Pro-Dex (NASDAQ:PDEX) Issues Quarterly Earnings Results, Beats Estimates By $0.11 EPS

Pro-Dex (NASDAQ:PDEXGet Free Report) posted its earnings results on Thursday. The medical instruments supplier reported $0.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.35 by $0.11, Yahoo Finance reports. The company had revenue of $15.03 million during the quarter. Pro-Dex had a return on equity of 6.50% and a net margin of 4.13%.

Pro-Dex Stock Performance

NASDAQ PDEX opened at $23.28 on Friday. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.45 and a quick ratio of 2.08. The company has a market cap of $79.62 million, a P/E ratio of 40.14 and a beta of 0.38. The stock has a 50-day moving average of $19.73 and a two-hundred day moving average of $18.85. Pro-Dex has a 1-year low of $14.51 and a 1-year high of $24.74.

Insider Activity

In related news, Director Angelita Rebamontan Domingo sold 2,585 shares of the company’s stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $18.30, for a total transaction of $47,305.50. Following the sale, the director now directly owns 8,191 shares of the company’s stock, valued at approximately $149,895.30. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 42.60% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, StockNews.com upgraded shares of Pro-Dex from a “buy” rating to a “strong-buy” rating in a report on Saturday.

Check Out Our Latest Research Report on Pro-Dex

About Pro-Dex

(Get Free Report)

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.

Read More

Earnings History for Pro-Dex (NASDAQ:PDEX)

Receive News & Ratings for Pro-Dex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pro-Dex and related companies with MarketBeat.com's FREE daily email newsletter.